Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Proposed dual-listing on Nasdaq

May 18, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has confidentially

Renalytix AI Announces Proposed Dual-listing on Nasdaq

May 18, 2020
NEW YORK, May 18, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has

Result of General Meeting

May 15, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that at the general meeting of the Company held today the resolution to cancel the share premium account of the Company and

Removal of US Securities Law Restrictions on Ordinary Shares

May 5, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces  that, following legal advice, it has taken the decision to remove the offering restrictions imposed by US securities law
Displaying 61 - 70 of 152